Innovation in oncology is biobank driven
02 Jul 2021

Cancer screening programs have almost come to a halt since the SARS-CoV-2 virus took hold. Colorectal and cervical cancer screening can, in some places, be done via a hybrid method of phone and kits for self-collection of samples; for breast cancer this is clearly not an option1. The delay in diagnosis and starting treatment can have severe consequences for the patients involved and indirectly also for research. In Europe alone, there are 46 biobanks involved in collecting, storing and managing samples of the aforementioned cancer types that have also seen their work change.

In this webinar, biobanking expert Erik Steinfelder will explore the role of biobanks in oncology research going forward and how their power can be fully unleashed to benefit the patient.

Attend the webinar to learn more about:

  • The important shift biobanks have made to support oncology research
  • Why biobanking goes beyond storing samples – it requires many disciplines that can have significant impact on research projects later in the process
  • Existing cross-disciplinary collaborations as role models going forward

Who Should Attend:

  • Biobanking professionals
  • Researchers using cryopreserved materials
  • Professionals working in the field of cancer diagnostics, cancer therapy, tumor biology and oncology research

Reference:

1. Basu P, Alhomoud S, Taghavi K, Carvalho AL, Lucas E, Baussano I. Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation. JCO Glob Oncol. 2021

Thermo Fisher Scientific